Compare Utah Medical Products, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 201 Million (Micro Cap)
14.00
NA
110.61%
-0.71
9.83%
1.70
Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Jun 2025)
Net Profit:
3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.52%
0%
4.52%
6 Months
-3.83%
0%
-3.83%
1 Year
-9.25%
0%
-9.25%
2 Years
-36.93%
0%
-36.93%
3 Years
-25.51%
0%
-25.51%
4 Years
-25.71%
0%
-25.71%
5 Years
-38.39%
0%
-38.39%
Utah Medical Products, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.47%
EBIT Growth (5y)
-3.25%
EBIT to Interest (avg)
16.41
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0.37
Tax Ratio
18.30%
Dividend Payout Ratio
30.42%
Pledged Shares
0
Institutional Holding
82.70%
ROCE (avg)
42.45%
ROE (avg)
12.53%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.56
EV to EBIT
7.70
EV to EBITDA
6.29
EV to Capital Employed
2.94
EV to Sales
2.52
PEG Ratio
NA
Dividend Yield
180.08%
ROCE (Latest)
38.15%
ROE (Latest)
11.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 49 Schemes (38.38%)
Foreign Institutions
Held by 32 Foreign Institutions (4.63%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
10.00
9.70
3.09%
Operating Profit (PBDIT) excl Other Income
4.00
3.90
2.56%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
3.00
3.00
Operating Profit Margin (Excl OI)
321.10%
324.70%
-0.36%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 3.09% vs 5.43% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 3.45% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
40.90
50.20
-18.53%
Operating Profit (PBDIT) excl Other Income
18.60
24.80
-25.00%
Interest
0.00
0.00
Exceptional Items
-2.10
-1.70
-23.53%
Consolidate Net Profit
13.90
16.60
-16.27%
Operating Profit Margin (Excl OI)
384.60%
367.10%
1.75%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -18.53% vs -4.02% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -16.27% vs 0.61% in Dec 2023
About Utah Medical Products, Inc. 
Utah Medical Products, Inc.
Pharmaceuticals & Biotechnology
Utah Medical Products, Inc. (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company's product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts. UTMD markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit, the labor and delivery department and the women's health center in hospitals, as well as products sold to outpatient clinics and physician's offices.
Company Coordinates 
Company Details
7043 S Cottonwood St , MIDVALE UT : 84047-1048
Registrar Details






